ストックスクリーナーアプリを入手
45.82
4.59%
2.01
プレマーケット:
45.14
-0.68
-1.48%
前日終値:
$43.81
開ける：
$44.7
24時間の取引高:
652.31K
Relative Volume:
2.53
時価総額：
$2.89B
収益：
-
当期純損益:
$-80.77M
株価収益率:
-36.08
EPS:
-1.27
ネットキャッシュフロー:
$-80.80M
1週間 パフォーマンス:
-1.46%
1か月 パフォーマンス:
-12.17%
6か月 パフォーマンス:
+2.41%
1年 パフォーマンス:
-14.40%
1日の値動き範囲:
$44.10
$47.02
1週間の範囲:
$41.27
$49.06
52週間の値動き範囲:
$37.55
$64.98
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
MLTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
45.82 | 2.89B | 0 | -80.77M | -80.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2024-11-05 | 再開されました | Wedbush | Outperform |
| 2024-08-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-02 | 開始されました | Goldman | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Citigroup | Buy |
| 2023-11-02 | 開始されました | Stifel | Buy |
| 2023-09-14 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 開始されました | Needham | Buy |
| 2023-06-15 | 開始されました | Barclays | Equal Weight |
| 2023-05-01 | 開始されました | Guggenheim | Buy |
| 2023-03-22 | 開始されました | Wedbush | Outperform |
| 2023-03-09 | 開始されました | BTIG Research | Buy |
| 2023-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 開始されました | Bryan Garnier | Buy |
| 2022-11-11 | 開始されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | SVB Leerink | Outperform |
| 2022-07-21 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-07 | 開始されました | Cowen | Outperform |
すべてを表示
Moonlake Immunotherapeutics (MLTX) 最新ニュース
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 6.3%Here's What Happened - MarketBeat
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN
Barclays PLC Purchases 5,229 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Comparing Petros Pharmaceuticals (NASDAQ:PTPI) & MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Goldman Sachs raises target price for dermatological drug maker MoonLake by 32% - Kursiv Media
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap UpHere's Why - MarketBeat
MoonLake upgraded at Goldman Sachs on promise of hidradenitis suppurativa asset - MSN
MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon - Seeking Alpha
Goldman Sachs Upgrades MoonLake Immunotherapeutics (MLTX) - MSN
This little-known biotech stock is a buy that’s primed to double in price, Goldman says - thepress.net
MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to Buy at The Goldman Sachs Group - MarketBeat
MoonLake Immunotherapeutics Sees Stock Target Shifts - TipRanks
How the (MLTX) price action is used to our Advantage - Stock Traders Daily
HC Wainwright Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $81.43 - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
MoonLake Immunotherapeutics initiates three new clinical trials - TipRanks
MLTX Crosses Below Key Moving Average Level - Nasdaq
MoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG - Yahoo Finance
MoonLake initiates three new clinical trials and further - GlobeNewswire
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab - Finansavisen
MoonLake Expands Sonelokimab Clinical Program with Three Groundbreaking Trials in Major Diseases - StockTitan
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Barclays PLC Acquires 5,229 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Long Term Trading Analysis for (MLTX) - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Position Raised by State Street Corp - Defense World
State Street Corp Increases Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 5.1%Time to Buy? - MarketBeat
When (MLTX) Moves Investors should Listen - Stock Traders Daily
Moonlake Immunotherapeutics Announces Resignation of Kara Lassen as Board Member, Effective December 31, 2024 - Marketscreener.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 3.2%Here's Why - MarketBeat
MoonLake Immunotherapeutics announces board change, incentive plan - Investing.com
MoonLake Immunotherapeutics Announces Board Changes and Incentives - TipRanks
MoonLake Immunotherapeutics announces board change, incentive plan By Investing.com - Investing.com UK
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 7.9%Here's What Happened - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate - Simply Wall St
Wellington Management Group LLP Cuts Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Trading (MLTX) With Integrated Risk Controls - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.6%What's Next? - MarketBeat
MoonLake Immunotherapeutics' SWOT analysis: stock outlook amid HS market potential - Investing.com
Clear Street sets $108 target on Moonlake Immunotherapeutics stock By Investing.com - Investing.com UK
Clear Street sets $108 target on Moonlake Immunotherapeutics stock - Investing.com
MoonLake Immunotherapeutics Reports Q3 2024 Financial Results - MSN
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
Erste Asset Management GmbH Invests $741,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Moonlake Immunotherapeutics (MLTX) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):